Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not true. Current CEO of Satellos is fantastic. Amazing Resume of past success
That presentation is over 2 years old. Recent presentations make no reference of Bert. CEO has stated he has no further interest in pursuing legacy assets. Full pedal to the metal on DMD research
Dude, what are you getting on about with Satellos? There is no merger with Naya. They have shelved Bert a long time ago and have their sole focus on DMD. Your posts are hysterical
Judging by the fact that the FDA/NIDA have given $5.7 million for its development you may have answered your own question. Would have to guess they have a better idea than you or i? No?
I wonder if alcoholism will be through and done by then as well.
You're not missing anything. That is the correct way of interpreting it
SEC filings on Nov/21st and Dec/14th
"On November 15, 2018, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) with LGH Investments, LLC, a Wyoming limited liability company (“LGH”) whereby LGH purchased from the Company, for a purchase price of $250,000 (the “Purchase Price”) (i) a Promissory Note of the Company, in the original principal amount of $275,000.00 (the “Note”); (ii) Two Hundred Fifty Thousand (250,000) restricted shares of the Company’s common stock (the “Common Stock”), par value $0.001 per share (the “Inducement Shares”);.."
"On December 12, 2018, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) with Vista Capital Investments, LLC, a California limited liability company (“VCI”) whereby VCI purchased from the Company, for a purchase price of $250,000 (the “Purchase Price”) (i) a Promissory Note of the Company, in the original principal amount of $275,000.00 (the “Note”); (ii) Two Hundred Fifty Thousand (250,000) restricted shares of the Company’s common stock (the “Common Stock”), par value $0.001 per share (the “Inducement Shares”);.."
"By potentially increasing our stock price, the Reverse Stock Split would potentially increase our minimum bid or share price required for the initial listing requirements for The Nasdaq Capital Market (“Nasdaq”). We currently do not meet the Nasdaq listing requirements, including the minimum bid price and shareholders’ equity. The Reverse Stock Split will not cause us to meet all of the listing requirements for Nasdaq. However, we believe the Reverse Stock Split will increase our stock price which may help us move towards eventually meeting the minimum share price requirements. We can provide no assurances that the Reverse Stock Split will have a long-term positive effect on the market price of our common stock, or increase our ability to be listed or approved for trading on Nasdaq."
"The Reverse Split was implemented by the Company in connection with the Company’s application to list its shares of common stock on the NASDAQ Capital Market (the “NASDAQ”). The Reverse Split is intended to fulfill, now or in the near future, the stock price requirements for listing on the NASDAQ since the requirements include, among other things, that the Company’s common stock must be, at time of listing, $4.00 or higher."
It's a deadline imposed by the SEC actually.
And there would be absolutely no purpose in setting a deadline with the SEC if they could SIMPLY issue a new one in a time efficient manner. Management clearly has a schedule that they are trying to abide by which is probably now behind due to the grant coming in late.
Are you suggesting that management is so far out of touch that they either are attempting to kill momentum, or are unaware of the effects of an RS on the stock price?
The news came out after hours on Friday. Not sure why you're talking about intraday price action
You can't say with certainty the reaction of the Grant and the RS on the market. Last time i saw a large RS combined with news was ETRM in 2016 which moved up over 1500%. I'm sure there are examples both ways, but there is not a clear answer. The Grant is incredibly positive news.
Also, as was mentioned previously, you need to assess the effects of an RS based on its purpose. Uplisting compared to maintaining a listed are VERY different. I'm sure that doesn't need an explanation.
GL
"The granting of discretionary authority to the Board of Directors of the Company (the “Board”), at any time or times for a period of 12 months after the date of the Written Consent, to Adopt an amendment to our Articles to effect a Reverse Split of our issued and outstanding common stock in a range of not less than 1-for-5 and not more than 1-for-500 (the “Reverse Split”). The form of this amendment to our Articles is attached as Appendix B. " -----Written consent was Jan/2018
I'm not sure why some are talking about the timing of the RS, and why management should have waited. 1 more week and they would have missed the deadline which is end of Jan/2019.
The Grant came months later than anticipated, which was in no way under their control.
I agree with everything that was done by management thus far given the circumstances. There were a lot of pessimistic posts here and naysayers about whether or not management could get this grant and they did. Overjoyed about that.
That's $5.6 million less that they would have needed to otherwise raise through investors or private placements.
Fantastic News!
Granier's plan to uplist.
This isn't new information. Was noted in previous SEC Filings
GLTA
Healthspace Data Systems - HS.CN
10 Bagger in 2019
LOL!
Fact of the matter is that the grant is supported by concrete facts about the company and its product. Have no clue why you are talking about carrots. Our impact score was 27, which is in the likelyhood of 95%+ of receiving grants if you do your research. Here's some info:
Q: What is an impact/priority score?
A: After discussing an application, members of the review group privately vote a numerical impact/priority score from 1 to 9, where 1 is best. The normalized average of all reviewer impact/priority scores constitutes the final impact/priority score. Impact scores run from 10 to 90, where 10 is best. Generally speaking, impact/priority scores of 10 to 30 are most likely to be funded; scores between 31 and 45 might be funded; scores greater than 46 are rarely funded. Before 2009, NIH used a different score system, with final scores from 100 to 500, where 100 was best.
I thought you were serious about asking if there was news today.
I tried to be as helpful as possible as i assumed if you weren't capable of completing a mundane task like checking a company website to see if there was news, you might need other things spelled out for you as well.
GLTU
Granier mentioned that we should be hearing back by Nov/15th - ish if i remember correctly.
Really should be any day now!
Please see NR from 2 weeks ago.
If you have any trouble reaching the website i'd be happy to post the most recent grant info for you.
biocorrx.com
I hold no position in this stock. It came across my radar and I find it interesting, but the Bear thesis on this is stronger than the Bull thesis. The bull thesis is simply “opioid addiction is a major problem, we need a solution!”
Let me help you out junior "opioid addiction is a major problem, we HAVE a solution!"
You have a lot more research to do, now get to it!
GLTU
https://ir.biocorrx.com/press-releases/detail/138
On the Company's website.
Enter your email in their Investor Relations page and you will receive emails when updates are put out by the company.
Also from that same article in August:
According to the NIH, the Company’s grant application is scheduled for scientific review this month. The Company expects to receive feedback on the review within a few weeks thereafter. BioCorRx has also added more experts to the Chemistry, Manufacturing, and Controls (CMC) team for BICX102, as well as an experienced project manager to coordinate the development plans. Ingredients for the implant have started to arrive and the build out for machinery and tooling needed for large scale manufacturing of the implant is nearing completion.
To me that sounds an awful lot like September ....
There was a NR about when they expect the grant money just recently. I believe it was 3rd week of September or something close to there.
Here's from Aug/07: Brady Granier, President, CEO and Director, stated, “While we wait for the grant review process to play out and for the remaining equipment and supplies to arrive, we are working diligently on the coordination and planning that is required for drug development. The procurement and build out of FDA quality machinery and ingredients are vital first steps that we have been working on aggressively behind the scenes for several months. In the interim, we have also added more experts from the industry to help in our planning so that we are fully prepared when we initiate the next phase of our drug development plan. We feel positive about the prospect of a grant award, but regardless of the results of the grant review, our plans are in place to start development work with the capital we have raised to date. We are fortunate to have many long term strategic investors supporting our efforts who believe in the product and management. We will continue to keep shareholders appraised as developments unfold.”
https://www.biocorrx.com/news-media/press-releases/detail/133/biocorrx-provides-update-on-bicx102
Strongly disagree. The company needs to continue as a going concern until grant money is received. They have chosen to fund the same way they always have. The $1.1 million from private investors was enough to bring them to this point or perhaps further.
They are not a day overdue for the grant money. No need to be making outlandish hypothesis
Having similar thoughts.
Have it checked off on my calendar to receive the news this week, as per their previous NR.
https://ir.biocorrx.com/press-releases/detail/135
I would imagine the Investors who bought $1.1 million @ .20 in the private placement were privy to information that made .20 seem like a deal. A 90% premium at the time.
I have not been worried in this position/stock, and i will continue to be confident.
.30+ before EOY
GLTA
I'm not sure they'd time it in that way. Once they receive material info then they should be releasing it to the public/shareholders. Biocorrx has been good with this sort of thing in the past.
As far as their wording in that Press Release i'd say 3rd or 4th week in September. They seemed to be ball-parking it anyhow. Sooner they receive and release it the better imo.
Press Release Aug/07/2018:
"According to the NIH, the Company’s grant application is scheduled for scientific review this month. The Company expects to receive feedback on the review within a few weeks thereafter. BioCorRx has also added more experts to the Chemistry, Manufacturing, and Controls (CMC) team for BICX102, as well as an experienced project manager to coordinate the development plans. Ingredients for the implant have started to arrive and the build out for machinery and tooling needed for large scale manufacturing of the implant is nearing completion."
Adda girl, bout time we saw some action.
A close above .13 would really set this in motion going forward
GLTA
Net loss reduced by over 50% in Quarter over '17, and 50% for 9 months compared to '17
Some wacky shiz going on @ .0084. MM's allowing covering or conversion @ .0084
I think we see @ .013 HOD in the next 2 hours
This gift in the .009's wont be here for much longer.
Won't stay in .009's long. Now is the time to add
Big flag forming on the 15 min
Do tell how you can tell when a "massive insider trading scheme is going on"
Strongest next resistance will be @ .0128-.0131
July 5-9 Support and July 17-18 Resistance
Closed above the 50 Day for the first time since the last jump in SP.
50 day is the wall that has this down for the past 12 days.
Very confident in seeing a positive movement toward testing .01, latest by Tuesday
Going to go back to .01 swiftly, without news.
Just the same as previous days, once CFGN is knocked out @ .0076 this will be well on its way ...
Incorrect sell to buy ratio.
Closer to 1:1 today.